The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Zymeworks BC Inc (NASDAQ: ZYME) was $13.58 for the day, up 6.59% from the previous closing price of $12.74. In other words, the price has increased by $6.59 from its previous closing price. On the day, 0.8 million shares were traded. ZYME stock price reached its highest trading level at $13.62 during the session, while it also had its lowest trading level at $12.67.
Ratios:
Our analysis of ZYME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.10 and its Current Ratio is at 4.10. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On November 07, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $10 to $25.
Wells Fargo Downgraded its Overweight to Equal Weight on November 01, 2024, while the target price for the stock was maintained at $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 05 ’24 when Galbraith Kenneth sold 18,198 shares for $10.65 per share. The transaction valued at 193,849 led to the insider holds 29,468 shares of the business.
Galbraith Kenneth sold 5,706 shares of ZYME for $63,996 on Jan 08 ’24. The Chair & CEO now owns 23,762 shares after completing the transaction at $11.22 per share. On Jan 05 ’24, another insider, Astle Christopher, who serves as the SVP & Chief Financial Officer of the company, sold 4,563 shares for $10.65 each. As a result, the insider received 48,606 and left with 7,934 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 935356480 and an Enterprise Value of 600577664. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.16 while its Price-to-Book (P/B) ratio in mrq is 2.60. Its current Enterprise Value per Revenue stands at 9.656 whereas that against EBITDA is -5.236.
Stock Price History:
Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is -3.96%, while the 200-Day Moving Average is calculated to be 22.13%.
Shares Statistics:
ZYME traded an average of 514.21K shares per day over the past three months and 448240 shares per day over the past ten days. A total of 69.58M shares are outstanding, with a floating share count of 66.65M. Insiders hold about 4.03% of the company’s shares, while institutions hold 97.11% stake in the company. Shares short for ZYME as of 1732838400 were 4632532 with a Short Ratio of 9.01, compared to 1730332800 on 4700126. Therefore, it implies a Short% of Shares Outstanding of 4632532 and a Short% of Float of 8.290000000000001.